This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JSM 6427

Shire Pharmaceuticals Group PLC

Drug Names(s): JSM 6427

Description: JSM 6427 is a small molecule a5ß1 integrin receptor antagonist. In comparison to other therapies, JSM 6427 not only blocks angiogenesis induced by multiple growth factors such as VEGF (Vascular Endothelial Growth Factor), but also inhibits the effects of other growth factors and cytokines leading to angiogenesis, inflammation, and fibrosis.

Deal Structure: In April 2008, Jerini AG and PRPharmaceuticals announced a license and development agreement between JeriniOphthalmic (JOI), a wholly-owned and independently operated US subsidiary of JeriniAG, and PR Pharmaceuticals (PRP). The collaboration agreement focuses on thedevelopment of sustained-release formulations (SRFs) for a range of ophthalmic indications,including JSM 6427. Under the terms of the agreement, JOI will pay an undisclosed upfront payment along with milestone payments for the achievement of preclinical and clinical goals androyalties on eventual product sales. In return, PRP agrees to cooperate exclusively with JOIon specified ophthalmic targets and to provide the company with all sustained-releaseformulations developed through the collaboration agreement.

In September 2008, Shire completed the acquisition of Jerini.

Abbvie and Shire
In July 2014, AbbVie and Shire announced that they have reached agreement on the terms of a recommended combination of...See full deal structure in Biomedtracker

Partners: PR Pharmaceuticals


JSM 6427 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug